American Century Companies Inc. Has $113.50 Million Stock Holdings in argenex SE $ARGX

American Century Companies Inc. raised its holdings in argenex SE (NASDAQ:ARGX) by 38.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 205,906 shares of the company’s stock after acquiring an additional 57,054 shares during the quarter. American Century Companies Inc. owned approximately 0.34% of argenex worth $113,503,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ARGX. Franklin Resources Inc. grew its stake in shares of argenex by 103.9% in the second quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after purchasing an additional 142,606 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in argenex by 33.2% during the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after buying an additional 68,498 shares during the period. Millennium Management LLC lifted its holdings in argenex by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after buying an additional 204,180 shares during the period. Jennison Associates LLC grew its position in shares of argenex by 6.1% in the 2nd quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock valued at $145,879,000 after buying an additional 15,186 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of argenex by 4.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 184,987 shares of the company’s stock valued at $100,350,000 after buying an additional 8,537 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenex Trading Down 1.3%

ARGX opened at $906.74 on Tuesday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.13. The company has a market cap of $55.83 billion, a price-to-earnings ratio of 38.93, a PEG ratio of 0.92 and a beta of 0.45. The company’s fifty day moving average price is $817.99 and its two-hundred day moving average price is $685.16.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. As a group, equities analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Evercore ISI lifted their price objective on argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. HC Wainwright boosted their price target on shares of argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company upped their price objective on shares of argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Truist Financial increased their price objective on shares of argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $903.78.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.